ASX Announcements

Appendix 3B Placement

Appendix 3B Rights Issue

 Appendix 3B Over Allotment Offer

Living Cell Technologies Limited is pleased to announce that it has executed a capital raise mandate with Alignment Capital Pty Ltd to raise up to approximately A$2.5M by way of three distinct funding initiatives:

• a placement for A$750,000;

• a non-renounceable rights issue entitlement offer, and shortfall offer by way of prospectus to raise circa A$1.2M; and

• a post rights issue over allotment offer to raise an additional A$562,500.

Living Cell Technologies Limited today announced the half yearly report for the six months ended 31 December 2022. 

Living Cell Technologies continues to advance its mission of improving the wellbeing of people with serious

diseases by discovering, developing, and commercialising novel treatments for debilitating conditions

such as Parkinson’s disease.